140
Views
4
CrossRef citations to date
0
Altmetric
Review

Epidemiology and treatment of autoimmune hepatitis

, , &
Pages 1-10 | Published online: 16 Mar 2012

Abstract

Autoimmune hepatitis (AIH) is a chronic inflammatory disease of the liver that occurs worldwide with a low and probably underestimated prevalence. Although it typically affects young and middle-aged women, it can occur in both sexes and across all age groups. AIH runs a fluctuating course, but can present as severe and even fulminant hepatic failure or at a stage of advanced fibrosis or cirrhosis. Prognosis of severe AIH is poor if untreated. The pathogenesis is complex, combining environmental factors (external chemical or infectious triggers) and host genetic susceptibility. The diagnosis is based, after exclusion of other etiologies of chronic liver disease, on a combination of different elements, including the presence of elevated transaminases, elevated immunoglobulin G (IgG) levels, the presence and pattern of typical autoantibodies, and a liver biopsy showing interface hepatitis and other characteristic features. No single test can be used to make the diagnosis. Response to treatment can also help to establish the diagnosis. Simplified criteria can be used to make a bedside diagnosis with relatively high accuracy. Treatment consists of corticosteroids or other immunosuppressive regimens according to the severity of the disease, the response to the treatment, and the tolerance to therapy, with liver transplantation as an ultimate remedy in treatment-resistant cases with liver decompensation.

Introduction

Autoimmune liver diseases are the earliest recognized sites of autoimmune diseasesCitation1,Citation2 and are classified in two main entities according to the target cell type of autoimmune injury.Citation3 In autoimmune hepatitis (AIH), hepatocytes are the target, whereas autoimmune cholangiopathies include disorders of the intrahepatic and extrahepatic biliary system with the cholangiocyte as main target.Citation4 In some cases both hepatocytes and cholangiocytes are involved, leading to overlap syndromes between AIH and autoimmune cholangiopathies.Citation5 This review will focus on AIH.

AIH is a chronic and progressive inflammatory disease of the liver, histologically characterized by an interface hepatitis.Citation3 The disease is further characterized by high but fluctuating levels of aspartate aminotransferase (AST), alanine aminotransferase and IgGs, and by the presence of autoantibodies.Citation1,Citation6,Citation7 Based on the latter, two types of AIH can be distinguished. Type 1 AIH (AIH-1) is characterized by the presence of antismooth muscle antibodies (ASMA) and/or antinuclear antibodies (ANA), where as type 2 AIH (AIH-2) typically shows positivity for antiliver/kidney microsome (LKM) type 1 antibodies or antiliver cytosol type 1 antibodies.Citation3,Citation8 Both types differ in age of onset, mode of presentation, geographic distribution, treatment, and successful treatment withdrawal rate.Citation7

Epidemiology and natural history

Data on AIH are rather scarce and suffer from important methodological shortcomings. Most of the data were collected before the introduction of the first International Autoimmune Hepatitis Group scoring system, implying a lack of standardization in diagnosis.Citation9,Citation10 Furthermore, most of the data were also collected before the discovery of hepatitis C virus (HCV). As patients with HCV are frequently positive for autoantibodies, some patients with HCV might have been misdiagnosed as having AIH.Citation11 Finally, the diagnosis is often overlooked and in both acute liver failure and the so-called cryptogenic cirrhosis many patients might actually have AIH without being properly diagnosed. For these reasons it is generally accepted that the reported incidences and prevalences are an underestimation of the true values.Citation7

Most of the available data are on AIH-1. AIH-1 represents about 80% of AIH cases, occurs worldwide,Citation3,Citation12,Citation13 and has a strong female predominance: 75% of affected people are female.Citation14 It was for a long time considered to primarily affect young and middle aged women, with a peak in childhood and another in adulthood around the age of 40.Citation3 It has, however, become clear that elderly people can also be affected and that the disease can have its first manifestation even at an advanced age: 20% of patients present after the age of 60 years.Citation15 In Norway the annual incidence was reported to be 1.9 cases per 100,000 with a prevalence of 17 cases per 100,000.Citation16 In the US an annual incidence of 1 per 200,000 cases was reported.Citation6 A Spanish report shows similar findings, with an annual incidence of 0.8 cases per 100,000 and a prevalence of 11.6 cases per 100,000Citation17 leading to an estimated point prevalence of 10 to 15 cases per 100,000.Citation4 The clinical presentation can be variable.Citation6,Citation15,Citation18 An incidental finding of elevated transaminases during a routine investigation may lead to its diagnosis. Nonspecific symptoms such as fatigue and arthralgia are often present. It can also present as an acute hepatitis or even as fulminant liver failure.Citation15 Recently an increase in the number of patients presenting with acute hepatitis has been reported in Japan.Citation19,Citation20 AIH often has a chronic and fluctuating course, and about 30% of patients already have cirrhosis at the time of diagnosis, indicative of a longstanding process.Citation21 Complications of cirrhosis may occasionally be the mode of presentation. Children and young adults often present with a more acute onset than elderly patients.Citation22

The course of AIH is therefore not always benign. Patients presenting with untreated severe disease are at high risk of death: 40% die within 6 months of diagnosis.Citation23 Those who survive develop cirrhosis in >40% of cases.Citation24 Patients with cirrhosis develop esophageal varices within 2 years in 54% of cases,Citation25 of whom 20% will eventually die of hemorrhage.Citation26 Sustained elevation of transaminases >10× upper limit of normal (ULN) or a combination of transaminases >5× ULN and gammaglobulins >2× ULN are predictors of early mortality.Citation27 AIH accounts for 2.6% of the liver transplantations in Europe and 5.9% in the US.Citation28,Citation29 Adequate treatment markedly improves prognosisCitation23,Citation25 with 10-year survival rates reaching 98%.Citation30,Citation31 The absence of normalization of transaminases while on treatment is associated with a poorer prognosis, including a higher risk of developing hepatocellular carcinoma.Citation30,Citation31

AIH-2 is thought to be less frequent, although it is probably underdiagnosed and underreported.Citation22 It mainly affects children and young adults and presents more frequently as fulminant hepatic failure.Citation32

Autoimmune liver diseases and AIH can present as a single-organ autoimmune disorder, but associated autoimmune disease of other organs can be observed and AIH can also present in the context of a systemic autoimmune disease.Citation3,Citation33 Autoimmune thyroiditis is most frequently encountered. Genetic predispostion might influence the susceptibility for concurrent extrahepatic disease.Citation34

Etiopathogenesis of AIH

AIH is a complex disease, in which environmental factors (external chemical or infectious triggers) and the host’s genetic susceptibility coinduce the loss of self-tolerance and subsequently the development of the disease.

Drug exposure is frequently present in AIH. Reactive metabolites created through hepatic metabolism of some drugs have been shown to bind to cellular proteins such as cytochrome P450. These can then be recognized by the immune system as neoantigens. Drug-induced AIH has been well documented for nitrofurantoin and minocycline, prompting a pattern of AIH not requiring long-term immunosuppressive therapy.Citation35,Citation36 Recently, antitumor necrosis factor (TNF)-α agents have been described as responsible for drug induced-AIH with favorable prognosis.Citation37 Moreover, the risk of recurrent drug induced liver injury (DILI) due to drugs such as cholesterol-lowering agents, TNF-α antagonists or antibiotics (such as fluoroquinolones) has to be considered. These drugs or their metabolites may share sufficient similarity to provide immunological cross-sensitization or they may share a common target leading to DILI as a consequence of the drug actions. In these cases the probability of making a diagnosis of AIH-DILI increases in the second episode.Citation38

Genetic predisposition is a prerequisite of AIH. The genes associated with AIH do not follow a Mendelian mode of inheritance; conversely, they operate as “complex trait conditions”, in which one or more genes act to increase or reduce the risk of the trait interacting with environmental factors.

The genes most strictly involved in AIH are located on the short arm of chromosome 6, within the human leukocyte antigen (HLA) class II region, with particular regard to the ones encoding allelic variants of DRB1.Citation39 AIH-1 susceptibility has been associated with DRB1*0301 and DRB1*0401Citation40,Citation41 in white North American and Northern European individuals and to DRB1*0405 and DRB1*0404 in Japan, Argentina, and Mexico.Citation42 In a Japanese population, DRB1*02 appears to be associated with a lower rate of concurrent autoimmune disease, whereas DRB1*04 is associated with higher IgG levels.Citation34 Moreover, in South American children, DRB1*1301 has been associated with an early-onset severe disease.Citation43 Conversely, AIH-2 susceptibility is related to DRB1*0701 and to DRB1*0301, the former having a worse outcome.Citation44 Interestingly, AIH can be present in 10% of patients affected by autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy, also known as autoimmune polyendocrine syndrome type 1, which is caused by homozygous mutations in the AIRE1 gene, a transcription factor involved in clonal deletion of self reactive T cells.Citation45 Additional possible susceptibility genes include TNF-α and -β, major histocompatibility complex-encoded complement, the major histocompatibility complex class I chain-related A and B,Citation46 cytotoxic T lymphocyte-associated antigen (CTLA) 4,Citation47 interleukin-2 (IL-2), IL-4 and IL-6,Citation48 and vitamin D receptorCitation49 genes.

Within these permissive genetic profiles infectious agents could have a possible role in the process of disease development. It has been hypothesized that the initiation of autoimmune damage is due to “molecular mimicry”, that is, to an immune response directed to a self-antigen structurally similar to external pathogens. In particular, shared homology can be identified between the cytochrome mono-oxygenase CYP2D6 and some viral epitopes, hence LKM-1 autoantibodies cross-react with homologous regions of CYP2D6, HCV, herpes simplex virus, and cytomegalovirus. According to this model the exposure to these pathogens may prime a cross-reactive subset of T cells in a genetically permissive background.Citation50,Citation51 Moreover, it has been reported that DRB1*1301 is associated with persistent hepatits A virus infection,Citation43 which highlights a possible role of hepatits A virus in the pathogenesis of AIH. Viral infections could also act as nonspecific triggers leading to nonspecific activation and proliferation of resting T cells, as reported in Epstein–Barr virus infection, or to the release of sequestered antigens from hepatocytes within a proinflammatory environment.Citation52 Moreover, among the bacterial agents, Coxiella burnetii could trigger an autoimmune liver disease.Citation53

The autoantigens associated with AIH are various. AIH-2 is a particular “disease model” since its autoantigen has been identified in the above-mentioned CYP2D6, which is the target of anti-LKM-1 autoantibodies. These autoantibodies recognize linear regions of CYP2D6 in a hierarchical manner, namely CYP2D6193–212 in 93%, CYP2D6257–269 in 85%, CYP2D6321–351 in 53%, CYP2D6410–429 in 13%, and CYP2D6373–389 in 7% of cases.Citation54 However, many other substrates can be encountered. The transfer ribonucleoprotein complex tRNP(Ser)Sec is bound by antisoluble liver antigen (SLA), 80 formiminotransferase cyclodeaminase is recognized by anti-liver cytosol type 1 and uridine triphosphate glucuronosyltransferase is recognized by anti-LKM-3.Citation55 Moreover, antibodies to liver microsomes primarily bind to cytochrome CYP1A2 and are associated with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy.Citation56 Interestingly, these autoantibodies were first described in patients with AIH induced by dihydralazine.Citation57

Various mechanisms underlie the autoimmune liver attack. Liver inflitrates in AIH reveal a predominant presence of CD4+ helper/inducer cells but also, albeit to a lesser extent, the presence of CD8+ cytotoxic/suppessor cells, natural killer (NK) cells, monocytes/macrophages and B lymphocytes.Citation58 A key role in liver damage is attributed to autoreactive CD4+ T lymphocytes that become activated after the presentation of a self antigenic peptide embraced by an HLA class II molecule by antigen-presenting cells and the interaction between receptors and coreceptors, such as CD28 expressed by CD4+ Th0 cells and CD80 expressed by antigen-presenting cells. The subsequent differentiation of the Th0 cells is influenced by the cytokine environment. IL-12 delivered by macrophages favors the differentiation into Th1, which in turn releases IL-2 and interferon-γ, that promote macrophage activation, stimulate CTLs, enhance the expression of HLA class I and induce the expression of HLA class II on hepatocytes (that is normally not present). Conversely, IL-4, IL-10, and IL-13 foster the production of antibodies by B lymphocytes.Citation7 These immunoglobulin G (IgG) coat the hepatocyte surface in AIH and render these cells susceptible to cytotoxic attacks by Fc-receptor-bearing cells, including NK. NK, besides inducing apoptosis, can also have an anti-inflammatory and immune suppressive role producing cytokines such as IL-4 and regulating the differentiation of T regulatory (T reg) cells.Citation59 Growing evidence has highlighted the role of immunoregulatory mechanisms, and in particular of their impairment, in AIH. Organ-specific autoimmunity is driven by the interplay between T effector and antigen-specific inducible T reg that determine the duration, extent, and distribution of inflammation within the organ.Citation60 T reg cells derive from CD4+ Th0 cells in the presence of transforming growth factor-β and constitutively express the CD25 (IL-2 receptor-α chain). In addition, they express CD62L (glucocorticoid-induced TNF receptor), CTLA4 and FOXP3 (forkhead/winged helix transcription factor), the latter being crucial for their function.Citation61 They prevent the proliferation of autoreactive cells, suppressing effector T cell immune responses. In AIH the number and function of T regs are impaired, especially at diagnosis and at relapse during drug-induced remission.Citation62,Citation63 Moreover, in children with AIH-2, the quantities of T reg inversely correlate with disease severity as well as with titers of anti-SLA and anti-LKM-1 autoantibodies.Citation61 In the presence of TGF-β and IL-6, Th0 differentiate into IL-17-producing T cells (Th17). This subset of cells has been recently described in human autoimmune liver diseases and AIH.Citation64,Citation65 IL-17 appeared to be significantly upregulated in animal models of AIHCitation66 and human AIH.Citation66,Citation67 It has been reported that there are increased levels of IL-17 in the peripheral blood of AIH patients and an expanded Th17 cell population both peripherially and within the liver, the latter data being positively correlated with the degree of inflammation and the stage of fibrosis.Citation67 Moreover, IL-17 stimulates IL-6 expression, which favors Th17 proliferation while reducing the development of T reg cells. Therefore, IL-17 may orientate the balance between Th17 and T reg cells towards Th17, which is critical for the development of autoimmune diseases.Citation67

Diagnosis

AIH should be considered in the differential diagnosis of patients with elevated liver enzymes and/or unexplained cirrhosis at any age. The diagnosis can be challenging given the absence of a single diagnostic marker and the variable clinical and laboratory findings. AIH is characterized by interface hepatitis, absence of other causes for the lesions eg, viral hepatitis or drug-induced hepatitis, and signs of autoimmunity (autoimmune antibodies or concomitant autoimmune diseases).Citation68

Autoantibodies

As outlined above, AIH results from loss of tolerance of immunocompetent cells to autologous hepatic tissue components and thus constitutes a pathogenetically inhomogeneous entity.Citation69 The presence and pattern of autoantibodies are important elements in establishing the diagnosis, in making the differential diagnosis with other immunemediated hepatobiliary diseases, and in identifying the type 1 or 2 variant.Citation3 We briefly discuss the most important autoantibodies.

Anti nuclear antibodies (ANA) can be considered as a generic term referring to antibodies with specificity for antigens in the cell nucleus. Antigens in the nucleus are present on nucleic acid molecules (RNA and DNA), or protein histones and nonhistones, and on determinants consisting of both nucleic acid and protein molecules (eg, the ribonucleoprotein antigen, antigen U-RNP). Different ANA have specificity for these different nuclear components. ANA are usually directed against double stranded DNA as in systemic lupus erythematosus but the target epitope appears to be different in both diseases.Citation70 ANA can be detected in patients serum using the conventional method by immunofluorescence or by the more recent enzyme-linked immunosorbent assay technique. They are typically positive in AIH-1.

Antismooth muscle antibodies (ASMA) show specificity for actin and other cytoskeleton components and are frequently present in AIH-1.Citation71,Citation72 Positivity for ASMA is, however, also seen in primary sclerosing cholangitis.

Anti-LKM-1, LKM-2, and LKM-3 and the liver microsomal type antibodies are microsomal auto-antibodies in AIH-2. As stated above, these antibodies are directed against the cytochrome 50 KD P450 db1 (CYP2D6) microsomal antigen and the 50 KD P450 2A2 antigen, respectively.Citation73,Citation74 Their staining pattern in the immunofluorescence assay is similar to those of antimitochondrial antibodies.

SLA antibodies are directed against cytosolic liver proteins identified as cytokeratins 8 and 18 which are also present in several other tissues.Citation75,Citation76 A more specific autoantibody against a cytosolic epitope is Anti-LC-1 (antibodies against liver-specific cytosol antigen type 1).

Liver membrane antibodies combine a set of antibodies against membrane lipoproteins, some of which are liver specific. One of the specific liver specific antibodies is anti-ASGP-R, which reacts with galactose residues of asialoglycoprotein receptor.

Perinuclear antineutrophil cytoplasmic antibodies are heterogenous auto-antibodies present in some patients with AIH.Citation3

Antimitochondrial antibodies are usually absent in AIH. If they are present, the diagnosis of primary biliary cirrhosis or an overlap syndrome should be considered.

Autoantibodies are not only useful in the diagnosis of AIH but might also have prognostic implications. SLA antibodies are particularly useful, as they are associated with a higher frequency of liver failure, severe histological alterations, long duration of treatment, and a high relapse rate after drug withdrawal.Citation77

Pathology

Liver biopsy remains essential in the diagnosis of AIH both to establish the diagnosis and to assess disease severity.Citation3 No histological findings are, however, pathognomonic. The most typical feature is interface hepatitis, which is found in the presence of an inflammatory infiltrate located at the membrana limitans of the portal area and extending into the surrounding liver parenchyma.Citation11,Citation18 Interface hepatitis can, however, also be present in other liver diseases, especially viral hepatitis. The infiltrate is typically lymphoplasmocytic. Plasma cells are abundantly present both at the portoparenchymal interface and in the liver lobules in typical cases, but lower numbers do not exclude a diagnosis of AIH.Citation7 Pyknotic necrosis and hepatocyte swelling are other typical but not pathognomonic features. The pathology can be severe, with extensive panlobular hepatitis. In fulminant cases, extensive necrosis and collapse can be seen. In a recent series zone 3 necrosis was a typical feature of patients presenting with acute hepatitis.Citation20 Advanced fibrosis or cirrhosis is frequently present, even in acute cases, illustrating the often longstanding chronic course of the disease. Patients presenting with bridging necrosis or multi-acinar necrosis progress to cirrhosis in 82% of cases within 5 years and have a mortality rate of 45%.Citation26

Liver biopsy can also show features of biliary damage pointing towards autoimmune cholangiopathy or overlap syndromesCitation78 and can also show features suggestive of other liver diseases.Citation8 The differential diagnosis with other liver diseases, especially with viral hepatitis and with DILI might be difficult, especially in less typical cases.Citation79

The heterogeneity of the clinical picture and the relative rarity of the disease often make the diagnosis difficult, especially in nonspecialist units. In 1993, the International Autoimmune Hepatitis Group (IAIHG), proposed a set of descriptive diagnostic criteria that were recommended in routine clinical practice to classify patients as having “definite” or “probable” AIH.Citation9 Female gender, elevation of the parenchymal liver enzymes AST or alanine aminotransferase, autoantibodies, negative viral markers, absence of hepatotoxic drugs or alcohol use, and autoimmune disease in patient or first-degree relatives, are considered typical for AIH. Features considered typical for AIH result in the addition of points, whereas features implicating other liver diseases result in a points decrease. Optional para meters are histological features and response to therapy. This scoring system was developed as a research tool. Czaja and Carpenter validated these criteria in 119 AIH patients.Citation80 The sensitivity for a definite diagnosis was 82% and specificity was 98%. The specificity for patients scoring a probable diagnosis was only 66%.

Scoring systems

In 1999 the IAIHG revised the criteria to reduce the likelihood of a probable diagnosis especially in patients with biliary tract disease.Citation10 In this revised scoring system, the treatment response is graded and a score can be considered before and after treatment. A pretreatment score of ten points or higher, or a posttreatment score of twelve points or higher indicate probable AIH. A pretreatment score of ten points has a sensitivity of 100%, specificity of 73%, and diagnostic accuracy of 67%. A pretreatment score of 15 points, indicative of “definite AIH” has a sensitivity of 95%, specificity of 97%, and diagnostic accuracy of 94%.Citation33

As the original scoring system and its revision are too complex for everyday use, the IAIHG developed a simplified scoring system, based on only four independent variables: presence and level of autoantibody expression by indirect immunofluorescence, serum IgG concentration, compatible or typical histological features, and the absence of viral markers.Citation81 This simplified score is presented in . The new simplified score was specifically designed to help at the bedside and not primarily for scientific studies. In addition, it was meant to also be applicable in countries with a high viral hepatitis rate. Its clinical usefulness and scientific validity has been assessed by many groups and has been found to be reliable in highly heterogeneous populations in different regions in the world.Citation33,Citation82Citation85 The median overall sensitivity for probable AIH (≥6 points) was 91% and specificity 94%. For those classified as definite AIH (≥7 points) the median overall sensitivity was 75.5% and specificity 100%.Citation33,Citation82,Citation83 Almost all these studies have a methodological problem (what is the gold standard?), as the included patients were based on the 1999 scoring system. Response to immunosuppressive therapy is such a characteristic hallmark of AIH that this criterion should be included in the final analysis of patients correctly classified as AIH; duration of inflammation more than 6 months should be documented to distinguish from drug-induced immune mediated hepatitis.

Table 1 Simplified diagnostic criteria for autoimmune hepatitis

Management of AIH

Indications for treatment

As outlined above, severe untreated AIH has a poor prognosis.Citation23 Prognosis can be markedly improved by adequate treatment. Based on the factors associated with a poor prognosis, absolute indications for treatment of AIH have been established. A few randomized, controlled trials have demonstrated that patients with AST levels of at least 10 × ULN or more than fivefold ULN in conjunction with a serum gammaglobulin level more than twofold ULN have a high mortality if untreated.Citation23,Citation25,Citation86,Citation87 The last placebo-controlled immunosuppressive trial containing an untreated arm was published in 1980.Citation87 The value of these studies is limited as the patients were not characterized by standard diagnostic criteria. Nevertheless these studies revealed that untreated patients have a very poor prognosis with 5- and 10-year survival rates of 50% and 10%, respectively. Histologic findings of bridging necrosis or multilobular necrosis at presentation progress to cirrhosis in 82% of untreated patients and are associated with a 5-year mortality of 45%.Citation26,Citation88,Citation89 Incapacitating symptoms, associated with hepatic inflammation such as fatigue and arthralgia, are also indications for treatment.Citation90

Symptomatic patients with serum AST and/or gammaglobulin levels less than the absolute criteria and with interface hepatitis, may also be indicated for immunosuppressive treatment on an individualized basis, balanced against the possible risk of therapy. Patients with minimal or no disease should not be treated but followed closely.

Immunosuppressive treatment should not be instituted in patients with serious pre-existing comorbidities (vertebral compression, psychosis, brittle diabetes, or uncontrolled hypertension), or previously known intolerance to steroids. Azathioprine should not be started in patients with severe pretreatment cytopenia (leukocyte <2.5 × 109/L or platelets <50 × 109/L) or known deficiency of thiopurine methyltransferase activity.Citation90 The present review will be limited to a discussion of the treatment regimens in adults.

Standard treatment

The standard treatment for AIH is based on the results of randomized trials in the 1970s, showing a survival benefit of corticosteroid treatment.Citation23,Citation25,Citation86 These trials also demonstrated the dismal prognosis of untreated symptomatic AIH, with 5-year survival below 25% in untreated patients versus 80% in those treated with corticosteroids.Citation87

The American Association for the Study of Liver Diseases practice guidelinesCitation90 recommends either monotherapy with prednisone at a starting dose of 40–60 mg daily, or a lower dose of prednisone (30 mg daily) combined with azathioprine (1–2 mg/kg body weight), based on the Mayo Clinic trial,Citation23 and can be considered evidence-based. Prednisone may be reduced by 10 mg per week to a maintenance dose of 20 mg. Further reductions can be considered to 10, 5, or 2.5 mg daily. The use of the prednisone metabolite prednisolone, used more frequently in Europe, is equally effective as chronic liver disease does not seem to have an effect on its synthesis.Citation26 A higher starting dose (1 mg/kg body weight) of prednisolone might induce remission more quickly and helps to spare steroids in long term.Citation91

Steroid-related side effects include acne, facial rounding, striae, weight gain, hirsutism, and emotional instability. Serious complications including steroid diabetes, osteopenia, aseptic bone necrosis, psychiatric symptoms, hypertension, and cataract formation should be anticipated in long-term treatment. Side effects are present in 80% of patients after 24 months of treatment. Azathioprine-related side effects include bone marrow suppression, nausea, vomiting, rash, cholestatic hepatitis, and pancreatitis. Cytopenia is not predictable by testing for thiopurine methyltransferase activity. Determination of this enzyme activity is only warranted when there is pretreatment or intratreatment cytopenia, or need for higher than conventional doses.Citation92 The overall frequency of azathioprine-related side effects in patients with AIH is 10% at a dose of 50 mg daily.Citation93

Outcomes of standard therapy can be classified as remission, relapse, and treatment failure. Complete remission is characterized by the disappearance of clinical symptoms and complete normalization of all inflammatory parameters including histology. It can be achieved in 65%–75% of patients after 24 months of treatment. As the histological resolution of inflammation lags behind the biochemical response by 3 to 6 months, therapy has to be continued beyond the normalization of aminotransferase levels. At least 3 years of continuous therapy is recommended.Citation90 Tapering regimens aiming at withdrawal should be attempted with great caution and only after obtaining a liver biopsy demonstrating a complete resolution of inflammatory activity. In that case predniso(lo)ne can be tapered over the course of 4–6 weeks to test whether a sustained remission has been achieved. While steroids are the drug of choice for induction of remission, azathioprine is the drug of choice for maintenance of remission.Citation94 Remission can be sustained by azathioprine monotherapy of 2 mg/kg daily.Citation95

Relapse is characterized by increase of aminotransferase levels and reoccurrence of clinical symptoms either under treatment, following tapering of steroids, or after complete withdrawal of therapy. It is present in 50% of patients within 6 months of treatment withdrawal and 80% after 3 years. Occurrence of a relapse requires reinitiation of standard therapy until remission. Therapy can then be tapered to monotherapy with azathioprine 2 mg/kg daily or low-dose prednisolone in patients intolerant to azathioprine. Attempts at withdrawal in all patients with longstanding (≥12 months) inactive disease can be considered.Citation96

Treatment failure, characterized by progression of the disease during standard therapy, is seen in about 10% of patients. In these cases the diagnosis of AIH should be carefully reconsidered. Experimental regimens can be administered.

Alternative treatments

Budesonide is a synthetic steroid with high first-pass metabolism in the liver of almost 90%, in principle capable of limiting systemic side effects compared with conventional steroids. Compared with prednisone, the absolute bioavailability is less than sixfold lower.Citation97 In a large European study a combination of budesonide and azathioprine was evaluated in noncirrhotic patients.Citation98 Budesonide at a dose of 3 mg three times daily (tapered to bid upon biochemical remission after 2 weeks, depending on clinical judgment) was compared with prednisone 40 mg daily (reduced per protocol) (both arms plus azathioprine 1–2 mg/kg daily). At 6 months, remission was achieved in 60% of the budesonide group but in only 39% of the prednisone group. In the budesonide group a substantial superior profile of steroid-related side effects was noted. It should be noted that the remission rate in the prednisone group is much worse than reported with a higher starting dose of prednisone and tapered according to biochemical response.Citation91 In addition, budesonide was not tested in cirrhosis because of possible shunting. However, the trial shows that budesonide can be considered a valid alternative in patients at risk of adverse effects from steroids.

In patients who are intolerant to azathioprine, mycophenolate mofetil (MMF) seems to be a relatively good alternative.Citation99Citation101 In another study of patients with AIH experiencing azathioprine failure or intolerance, however, there was no significant benefit with MMF.Citation102 There are, however, no controlled clinical trials evaluating MMF in treatment naïve or treatment experienced patients with AIH. In a recent prospective study, MMF in combination with prednisolone was evaluated as an alternative to azathioprine in the first-line treatment of AIH. Biochemical response rates were excellent with 88% of the 59 patients achieving complete remission within the first year of treatment.Citation103 Using MMF as first line treatment of patients with AIH has several drawbacks such as costs (about 15 times higher than azathioprine) and teratogenicity.Citation104

Calcineurin inhibitors (cyclosporine A, tacrolimus) have also been used.Citation105Citation107 The principal difficulty in advocating for these drugs in first-line therapy relates to their toxicity profile particularly with long-term use. Furthermore, these drugs are not immunomodulatory and therefore require permanent treatment.

Liver transplantation is the treatment of choice in case of fulminant hepatic failure and those who progress to end-stage liver disease despite immunosuppression.

Conclusion

AIH is a chronic inflammatory disease of the liver occurring worldwide in both sexes and across all age groups. The pathogenesis is complex, combining environmental and genetic factors. The diagnosis is based on a combination of elevated transaminases, the presence and pattern of typical autoantibodies, and a liver biopsy showing interface hepatitis and other typical features. Response to treatment can also help to establish the diagnosis. Simplified criteria can be used to make a bedside diagnosis with relatively high accuracy. Treatment consists of corticosteroids or other immunosuppressive regimens according to the severity of the disease, the response to treatment, and the tolerance to therapy.

Acknowledgments

The authors thank Samuel Wamutu for carefully reading and correcting the manuscript.

Disclosures

The authors report no conflicts of interest in this work.

References

  • InvernizziPMackayIRAutoimmune liver diseasesWorld J Gastroenterol2008143290329118528925
  • CooperGSStroehlaBCThe epidemiology of autoimmune diseasesAutoimmun Rev2003211912512848952
  • MannsMPVerganiDAutoimmune hepatitisSemin Liver Dis20092923924019675996
  • InvernizziPGeoepidemiology of autoimmune liver diseasesJ Autoimmun201034J300J30620036105
  • RustCBeuersUOverlap syndromes among autoimmune liver diseasesWorld J Gastroenterol2008143368337318528934
  • MannsMLuttigBObermayer-StraubPAutoimmune HepatitisRoseNMackayIThe Autoimmune Diseases3rd edAmsterdamElsevier Academic Press1998511525
  • Mieli-VerganiGVerganiDAutoimmune hepatitisNat Rev Gastroenterol Hepatol2011832032921537351
  • CzajaAJFreeseDKDiagnosis and treatment of autoimmune hepatitisHepatology20023647949712143059
  • JohnsonPJMcFarlaneIGMeeting report: International Autoimmune Hepatitis GroupHepatology19931899810058406375
  • AlvarezFBergPABianchiFBInternational Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitisJ Hepatol19993192993810580593
  • CzajaAJCarpenterHAHistological findings in chronic hepatitis C with autoimmune featuresHepatology1997264594669252159
  • GuptaRAgarwalSRJainMMalhotraVSarinSKAutoimmune hepatitis in the Indian subcontinent: 7 years experienceJ Gastroenterol Hepatol2001161144114811686842
  • LimKNCasanovaRLBoyerTDBrunoCJAutoimmune hepatitis in African Americans: presenting features and response to therapyAm J Gastroenterol2001963390339411774954
  • CzajaAJdos SantosRMPortoASantrachPJMooreSBImmune phenotype of chronic liver diseaseDig Dis Sci199843214921559753285
  • FerrariRPappasGAgostinelliDType 1 autoimmune hepatitis: patterns of clinical presentation and differential diagnosis of the ‘acute’ typeQJM20049740741215208428
  • BobergKMAadlandEJahnsenJRaknerudNStirisMBellHIncidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian populationScand J Gastroenterol199833991039489916
  • PrimoJMerinoCFernandezJMolesJRLlorcaPHinojosaJIncidence and prevalence of autoimmune hepatitis in the area of the Hospital de Sagunto (Spain)Gastroenterol Hepatol20042723924315056409
  • KrawittELAutoimmune hepatitisN Engl J Med2006354546616394302
  • AbeMMashibaTZeniyaMYamamotoKOnjiMTsubouchiHPresent status of autoimmune hepatitis in Japan: a nationwide surveyJ Gastroenterol2011461136114121597932
  • MiyakeYIwasakiYKobashiHAutoimmune hepatitis with acute presentation in JapanDig Liver Dis201042515419473895
  • RobertsSKTherneauTMCzajaAJPrognosis of histological cirrhosis in type 1 autoimmune hepatitisGastroenterology19961108488578608895
  • GregorioGVPortmannBReidFAutoimmune hepatitis in childhood: a 20-year experienceHepatology1997255415479049195
  • SolowayRDSummerskillWHBaggenstossAHClinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosisGastroenterology1972638208334538724
  • MistilisSPSkyringAPBlackburnCRNatural history of active chronic hepatitis. I. Clinical features, course, diagnostic criteria, morbidity, mortality and survivalAustralas Ann Med1968172142235684607
  • Murray-LyonIMSternRBWilliamsRControlled trial of prednisone and azathioprine in active chronic hepatitisLancet197317357374121073
  • SchalmSWKormanMGSummerskillWHCzajaAJBaggenstossAHSevere chronic active liver disease. Prognostic significance of initial morphologic patternsAm J Dig Dis197722973980920708
  • De GeestJFeveryJLepoutreLLong-term follow-up of chronic active hepatitis of moderate severityGut197819510513680585
  • MilkiewiczPHubscherSGSkibaGHathawayMEliasERecurrence of autoimmune hepatitis after liver transplantationTransplantation19996825325610440397
  • WiesnerRHDemetrisAJBelleSHAcute hepatic allograft rejection: incidence, risk factors, and impact on outcomeHepatology1998286386459731552
  • MiyakeYIwasakiYTeradaRPersistent elevation of serum alanine aminotransferase levels leads to poor survival and hepatocellular carcinoma development in type 1 autoimmune hepatitisAliment Pharmacol Ther2006241197120517014578
  • MiyakeYIwasakiYTeradaRPersistent normalization of serum alanine aminotransferase levels improves the prognosis of type 1 autoimmune hepatitisJ Hepatol20054395195716143423
  • OettingerRBrunnbergAGernerPWintermeyerPJenkeAWirthSClinical features and biochemical data of Caucasian children at diagnosis of autoimmune hepatitisJ Autoimmun200524798415725580
  • CzajaAJPerformance parameters of the diagnostic scoring systems for autoimmune hepatitisHepatology2008481540154818924244
  • MiyakeYIwasakiYTakakiAHuman leukocyte antigen DR status and clinical features in Japanese patients with type 1 autoimmune hepatitisHepatol Res2008389610217970717
  • BjornssonETalwalkarJTreeprasertsukSDrug-induced autoimmune hepatitis: clinical characteristics and prognosisHepatology2010512040204820512992
  • CzajaAJDrug-induced autoimmune-like hepatitisDig Dis Sci20115695897621327704
  • EfeCPurnakTOzaslanEWahlinSDrug-induced autoimmune hepatitis caused by anti-tumor necrosis factor alpha agentsHepatology2010522246224720715094
  • LucenaMIKaplowitzNHallalHRecurrent drug-induced liver injury (DILI) with different drugs in the Spanish Registry: the dilemma of the relationship to autoimmune hepatitisJ Hepatol20115582082721338638
  • DonaldsonPTGenetics of liver disease: immunogenetics and disease pathogenesisGut20045359960815016758
  • DohertyDGDonaldsonPTUnderhillJAAllelic sequence variation in the HLA class II genes and proteins in patients with autoimmune hepatitisHepatology1994196096158119685
  • StrettellMDThomsonLJDonaldsonPTBunceMO’NeillCMWilliamsRHLA-C genes and susceptibility to type 1 autoimmune hepatitisHepatology199726102310269328330
  • CzajaAJDonaldsonPTGenetic susceptibilities for immune expression and liver cell injury in autoimmune hepatitisImmunol Rev200017425025910807521
  • FainboimLMarcosYPandoMChronic active autoimmune hepatitis in children. Strong association with a particular HLA-DR6 (DRB1*1301) haplotypeHum Immunol1994411461507860360
  • MaYBogdanosDPHussainMJPolyclonal T-cell responses to cytochrome P450IID6 are associated with disease activity in autoimmune hepatitis type 2Gastroenterology200613086888216530525
  • ListonALesageSGrayDHBoydRLGoodnowCCGenetic lesions in T-cell tolerance and thresholds for autoimmunityImmunol Rev20052048710115790352
  • StrassburgCPAutoimmune hepatitisBest Pract Res Clin Gastroenterol20102466768220955969
  • AgarwalKCzajaAJJonesDEDonaldsonPTCytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphisms and susceptibility to type 1 autoimmune hepatitisHepatology200031495310613727
  • FanLYTuXQZhuYGenetic association of cytokines polymorphisms with autoimmune hepatitis and primary biliary cirrhosis in the ChineseWorld J Gastroenterol2005112768277215884119
  • VogelAStrassburgCPMannsMPGenetic association of vitamin D receptor polymorphisms with primary biliary cirrhosis and autoimmune hepatitisHepatology20023512613111786968
  • LonghiMSMaYMieli-VerganiGVerganiDAetiopathogenesis of autoimmune hepatitisJ Autoimmun20103471419766456
  • ChristenUHintermannEHoldenerMvon HerrathMGViral triggers for autoimmunity: is the ‘glass of molecular mimicry’ half full or half empt?J Autoimmun201034384419716269
  • VentoSGuellaLMirandolaFEpstein–Barr virus as a trigger for autoimmune hepatitis in susceptible individualsLancet19953466086097651006
  • KaechCPacheIRaoultDGreubGCoxiella burnetii as a possible cause of autoimmune liver disease: a case reportJ Med Case Reports200938870
  • KerkarNChoudhuriKMaYCytochrome P4502D6(193–212): a new immunodominant epitope and target of virus/self cross-reactivity in liver kidney microsomal autoantibody type 1-positive liver diseaseJ Immunol20031701481148912538711
  • MannsMPObermayer-StraubPCytochromes P450 and uridine triphosphate-glucuronosyltransferases: model autoantigens to study drug-induced, virus-induced, and autoimmune liver diseaseHepatology199726105410669328334
  • ClementeMGObermayer-StraubPMeloniACytochrome P450 1A2 is a hepatic autoantigen in autoimmune polyglandular syndrome type 1J Clin Endocrinol Metab199782135313619141515
  • MannsMPGriffinKJQuattrochiLCIdentification of cytochrome P450IA2 as a human autoantigenArch Biochem Biophys19902802292322353823
  • SenaldiGPortmannBMowatAPMieli-VerganiGVerganiDImmunohistochemical features of the portal tract mononuclear cell infiltrate in chronic aggressive hepatitisArch Dis Child199267144714531489223
  • ZhangCZhangJTianZThe regulatory effect of natural killer cells: do “NK-reg cells” exis?Cell Mol Immunol2006324125416978532
  • VierlingJMAutoimmune hepatitis and antigen-specific T regulatory cells: when can we send in the regulator?Hepatology20115338538821274860
  • OoYHHubscherSGAdamsDHAutoimmune hepatitis: new paradigms in the pathogenesis, diagnosis, and managementHepatol Int2010447549320827405
  • LonghiMSMaYBogdanosDPCheesemanPMieli-VerganiGVerganiDImpairment of CD4(+)CD25(+) regulatory T-cells in autoimmune liver diseaseJ Hepatol200441313715246204
  • LonghiMSMedaFWangPExpansion and de novo generation of potentially therapeutic regulatory T cells in patients with autoimmune hepatitisHepatology20084758159118220288
  • HaradaKShimodaSSatoYIsseKIkedaHNakanumaYPeriductal interleukin-17 production in association with biliary innate immunity contributes to the pathogenesis of cholangiopathy in primary biliary cirrhosisClin Exp Immunol200915726127019604266
  • LemmersAMorenoCGustotTThe interleukin-17 pathway is involved in human alcoholic liver diseaseHepatology20094964665719177575
  • YuHHuangJLiuYIL-17 contributes to autoimmune hepatitisJ Huazhong Univ Sci Technolog Med Sci20103044344620714867
  • ZhaoLTangYYouZInterleukin-17 contributes to the pathogenesis of autoimmune hepatitis through inducing hepatic interleukin-6 expressionPLoS One20116e1890921526159
  • LohseAWWiegardCDiagnostic criteria for autoimmune hepatitisBest Pract Res Clin Gastroenterol20112566567122117633
  • KruegerGRamonABujaLMKruegerGRFRamonAMCImmunopathology of Liver Diseases. An Overview. Diagnostical and Clinical AspectsHouston, TXInternational Institute of Immunopathology, Inc1999
  • GurianLERogoffTMWareAJJordanRECombesBGilliamJNThe immunologic diagnosis of chronic active “autoimmune” hepatitis: distinction from systemic lupus erythematosusHepatology198553974023873387
  • KurkiPVirtanenIThe detection of smooth muscle antibodies reacting with intermediate filaments of desmin typeJ Immunol Methods1985763293353882841
  • VirtanenILehtoVPLehtonenEExpression of intermediate filaments in cultured cellsJ Cell Sci19815045637033254
  • RizzettoMSwanaGDoniachDMicrosomal antibodies in active chronic hepatitis and other disordersClin Exp Immunol1973153313444587503
  • MannsMPJohnsonEFGriffinKJTanEMSullivanKFMajor antigen of liver kidney microsomal autoantibodies in idiopathic autoimmune hepatitis is cytochrome P450db1J Clin Invest198983106610722466049
  • MannsMGerkenGKyriatsoulisAStaritzMMeyer zum BuschenfeldeKHCharacterisation of a new subgroup of autoimmune chronic active hepatitis by autoantibodies against a soluble liver antigenLancet198712922942880112
  • WachterBKyriatsoulisALohseAWGerkenGMeyer zum BuschenfeldeKHMannsMCharacterization of liver cytokeratin as a major target antigen of anti-SLA antibodiesJ Hepatol1990112322391701454
  • CzajaAJAutoantibodies as prognostic markers in autoimmune liver diseaseDig Dis Sci2010552144216120464491
  • McHutchisonJGGordonSCSchiffERInterferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy GroupN Engl J Med1998339148514929819446
  • SuzukiABruntEMKleinerDEThe use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injuryHepatology20115493193921674554
  • CzajaACarpenterHAValidation of scoring system for diagnosis of autoimmune hepatitisDig Dis Sci1996413053148601374
  • HennesEMZeniyaMCzajaAJSimplified criteria for the diagnosis of autoimmune hepatitisHepatology20084816917618537184
  • MuratoriPGranitoAPappasGMuratoriLValidation of simplified diagnostic criteria for autoimmune hepatitis in Italian patientsHepatology2009491782178319402135
  • YeomanADWestbrookRHAl-ChalabiTDiagnostic value and utility of the simplified International Autoimmune Hepatitis Group (IAIHG) criteria in acute and chronic liver diseaseHepatology20095053854519575457
  • GatselisNKZachouKPapamichalisPComparison of simplified score with the revised original score for the diagnosis of autoimmune hepatitis: a new or a complementary diagnostic scor?Dig Liver Dis20104280781220399157
  • QiuDWangQWangHValidation of the simplified criteria for diagnosis of autoimmune hepatitis in Chinese patientsJ Hepatol20115434034721056494
  • CookGCMulliganRSherlockSControlled prospective trial of corticosteroid therapy in active chronic hepatitisQ J Med1971401591854933363
  • KirkAPJainSPocockSThomasHCSherlockSLate results of the Royal Free Hospital prospective controlled trial of prednisolone therapy in hepatitis B surface antigen negative chronic active hepatitisGut19802178836988304
  • BaggenstossAHSolowayRDSummerskillWHElvebackLRSchoenfieldLJChronic active liver disease. The range of histologic lesions, their response to treatment, and evolutionHum Pathol197231831985028616
  • CooksleyWGBradbearRARobinsonWThe prognosis of chronic active hepatitis without cirrhosis in relation to bridging necrosisHepatology198663453483710424
  • MannsMPCzajaAJGorhamJDDiagnosis and management of autoimmune hepatitisHepatology2010512193221320513004
  • KanzlerSLohrHGerkenGGallePRLohseAWLong-term management and prognosis of autoimmune hepatitis (AIH): a single center experienceZ Gastroenterol200139339811413913
  • CzajaAJSafety issues in the management of autoimmune hepatitisExpert Opin Drug Saf2008731933318462189
  • SummerskillWHKormanMGAmmonHVBaggenstossAHPrednisone for chronic active liver disease: dose titration, standard dose, and combination with azathioprine comparedGut1975168768831104411
  • StellonAJKeatingJJJohnsonPJMcFarlaneIGWilliamsRMaintenance of remission in autoimmune chronic active hepatitis with azathioprine after corticosteroid withdrawalHepatology198887817843292363
  • JohnsonPJMcFarlaneIGWilliamsRAzathioprine for long-term maintenance of remission in autoimmune hepatitisN Engl J Med19953339589637666914
  • CzajaAJMenonKVCarpenterHASustained remission after corticosteroid therapy for type 1 autoimmune hepatitis: a retrospective analysisHepatology20023589089711915036
  • ThalenABrattsandRSynthesis and anti-inflammatory properties of budesonide, a new non-halogenated glucocorticoid with high local activityArzneimittelforschung19792916871690543875
  • MannsMPWoynarowskiMKreiselWBudesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitisGastroenterology20101391198120620600032
  • RichardsonPDJamesPDRyderSDMycophenolate mofetil for maintenance of remission in autoimmune hepatitis in patients resistant to or intolerant of azathioprineJ Hepatol20003337137511019991
  • DevlinSMSwainMGUrbanskiSJBurakKWMycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory to standard therapyCan J Gastroenterol20041832132615152283
  • ChaturNRamjiABainVGTransplant immunosuppressive agents in non-transplant chronic autoimmune hepatitis: the Canadian association for the study of liver (CASL) experience with mycophenolate mofetil and tacrolimusLiver Int20052572372715998421
  • HennesEMOoYHSchrammCMycophenolate mofetil as second line therapy in autoimmune hepatiti?Am J Gastroenterol20081033063307018853972
  • ZachouKGatselisNPapadamouGRigopoulouEIDalekosGNMycophenolate for the treatment of autoimmune hepatitis: prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-naive patientsJ Hepatol20115563664621238519
  • SchrammCLohseAWRole of mycophenolate mofetil in the treatment of autoimmune hepatitisJ Hepatol20115551051121281682
  • FernandesNFRedekerAGVierlingJMVillamilFGFongTLCyclosporine therapy in patients with steroid resistant autoimmune hepatitisAm J Gastroenterol1999942412489934764
  • Van ThielDHWrightHCarrollPTacrolimus: a potential new treatment for autoimmune chronic active hepatitis: results of an openlabel preliminary trialAm J Gastroenterol1995907717767537444
  • AqelBAMachicaoVRosserBSatyanarayanaRHarnoisDMDicksonRCEfficacy of tacrolimus in the treatment of steroid refractory autoimmune hepatitisJ Clin Gastroenterol20043880580915365410